ClinicalTrials.gg
CompletedNCT05162768NuPowerUpdated Oct 24, 2025

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

A Phase 3 interventional study of Elamipretide and Placebo in Mitochondrial Myopathies, Mitochondrial Pathology and Mitochondrial DNA Mutation, sponsored by Stealth BioTherapeutics Inc.. Completed at 32 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Stealth BioTherapeutics Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.

Enrollment
2nd of 12
102 · median 50
Started
2022
with 1 other
Phase 3
Only one
of the 19
Registered
13th of 19
by date
Lead sponsor
4 of 19
Stealth BioTherapeutics Inc.

Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 3, and was the 13th registered.

Mitochondrial Myopathies

46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.

Browse Mitochondrial Myopathies studies →

Open to participants now

6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mitochondrial Myopathies with a site in United States, or all of them as a file.
02

Study summary

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).

Read the detailed description

This 48-week randomized, double-blind, parallel-group, placebo-controlled trial will enroll approximately 130 subjects, consisting of 90 subjects who have nPMD associated with pathogenic mutations of the mitochondrial replisome("replisome-related mutations") for primary analysis and an additional subset of up to 40 subjects who have nPMD associated with other non-replisome-related pathogenic mutations specific to the nuclear DNA. Efficacy and safety of single daily SC doses of elamipretide administered as a treatment for subjects who have primary mitochondrial myopathy associated with nPMD will be determined. Subjects will be randomized 1:1 to 60mg Elamipretide or matching placebo groups.

03

Conditions studied

  • Mitochondrial Myopathies
  • Mitochondrial Pathology
  • Mitochondrial DNA Mutation
  • Mitochondrial Diseases
  • Mitochondrial DNA Deletion
  • Mitochondrial DNA Depletion
  • Mitochondrial Metabolism Defect
  • Mitochondrial Complex I Deficiency

Keywords

  • primary mitochondrial myopathy (PMM)
  • nuclear DNA mutations n(PMD)
  • exercise intolerance
  • muscle weakness
  • mitochondrial dysfunction
  • POLG
  • TWINKLE
  • progressive external ophthalmoplegia
  • Elamipretide
  • mitochondrial replisome
  • replisome related mutations
  • MTP-131
  • primary mitochondrial disease (PMD)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject must meet all of the following inclusion criteria at the Screening and Baseline Visit (unless otherwise specified) to be eligible for inclusion in the SPIMD-301 trial:

  1. Willing and able to provide a signed form (ICF) prior to participation in any trial-related procedures.
  2. Agrees and is able to adhere to the trial requirements for the length of the trial, including administration of assigned treatment.
  3. Is ≥18 years and ≤ 70 years of age at the time of screening.
  4. Diagnosed with nPMD with a predominant clinical manifestation of myopathy, which must include progressive external ophthalmoplegia (PEO) and exercise intolerance and/or skeletal muscle weakness, with genetic confirmation of either:

    1. Nuclear DNA mutation of the mitochondrial replisome (replisome-related mutations), which include the following genes:

      • POLG 1/2
      • TWINKLE (C10ORF2)
      • TYMP
      • DGUOK
      • TK2
      • RRM2B
      • RNASEH1
      • SSBP
      • MGME1
      • DNA2
      • ANT1 (SLC25A4)
      • SUCLG1
      • SUCLA2
      • MPV17 or
    2. Other pathogenic mutations specific to nuclear DNA.
  5. Women of must agree to use one of the following methods of from the date they sign the ICF until 28 days after the last dose of IMP:

    1. Abstinence, when it is in line with the preferred and usual lifestyle of the subject. Subject agrees to use a highly effective method of contraception should they become sexually active.
    2. Relationships with male partners who have been surgically sterilized by vasectomy (the vasectomy procedure must have been conducted at least 60 days prior to the Screening Visit).
    3. Barrier method (e.g., condom or occlusive cap) with spermicidal foam/gel/film/cream AND either hormonal contraception (oral, implanted, or injectable) or an intrauterine device or system.

    Note: Non-childbearing potential is defined as surgical sterilization (e.g., bilateral oophorectomy, hysterectomy, or tubal ligation) or (defined as permanent cessation of menstruation for at least 12 consecutive months prior to the Screening Visit).

  6. Male subjects with female partners of childbearing potential must be willing to use a highly effective method of contraception from the date they sign the ICF until 28 days after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  1. Is unable to perform the 6MWT, 3TUG, or 5XSST functional tests. The use of a gait assist device is allowed; however, use should remain consistent for the entire duration of the trial.
  2. Female subjects who are pregnant, planning to become pregnant, or breastfeeding/lactating.
  3. Walks \< 150 meters or > 450 meters during the 6MWT (Screening Visit only).
  4. The estimated (eGFR) is \< 30 mL/min/1.73 m2, using the Modification of Diet in Renal Disease (MDRD) Study equation (Screening Visit only).
  5. Has undergone an in-patient hospitalization within 30 days prior to screening or has a planned hospitalization or a surgical procedure during the trial, unless, in the opinion of the Investigator, it is concluded that it will not impact the outcome measurements of the trial.
  6. Has respiratory disease and/or cardiac disease that would interfere with trial assessments, in the opinion of the Investigator.
  7. Has had any prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening.
  8. Has history of or current severe neurologic impairment, severe epilepsy, severe ataxia, or severe neuropathy that may interfere with their ability to complete all trial requirements, in the opinion of the Investigator.
  9. Active or any other cancer from which the subject has been disease-free for \< 2 years. Localized squamous or non-invasive basal cell skin carcinomas are allowed, if appropriately treated prior to screening.
  10. Has had a solid organ transplant.
  11. Has been previously diagnosed with (HIV), , or infection.
  12. Has a history of a systemic eosinophilic illness and/or an eosinophil count >1,000 cells x106/L at the Screening Visit.
  13. Is currently participating or has participated in an interventional clinical trial (i.e., product or device, stem cell therapy, gene therapy) within 30 days prior to current trial; or is currently enrolled in a non-interventional clinical trial that, in the opinion of the Investigator, may be potentially confounding to the results of the current trial (e.g., exercise therapy trial).
  14. Has received elamipretide (MTP-131) within the past one year of the Screening Visit.
  15. Has a history of active substance abuse during the year prior, in the opinion of the Investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Elamipretide

    0.75 mL of 80mg/mL solution of elamipretide for a single daily SC dose of 60mg elamipretide

    Drug: Elamipretide

  • Placebo comparator
    Placebo

    0.75 mL of 80mg/mL solution of matching placebo for a single daily SC dose of 60mg

    Drug: Placebo

Interventions

  • 60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks

    Also known as: MTP-131

  • DrugPlacebo

    Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks

06

What researchers measure

Primary outcomes

  1. Six-minute walk test (6MWT)

    Change from Baseline in Distance Walked (in meters) on the Six-Minute Walk Test by Visit

    Time frame: Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit)

Secondary outcomes

  1. 5 times sit-to-stand test (5XSST)

    Change from Baseline in Total time (in seconds) to complete the 5XSST. Participant is directed to stand up straight as quickly as possible 5 times, without stopping in between, keeping arms folded across the chest. An average time is calculated.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit)

  2. Triple Timed up-and-go test (3TUG)

    Change from Baseline in Total time (in seconds) to complete the 3TUG. Participant is directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away, turn, walk back to the chair at normal pace, sit down again; activity is timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit)

  3. Patient Global Impression of Severity (PGI-S) Scale

    Change from Baseline for PGI of Severity (PGI-S) Scale. Patient-reported current health status by week and at end of treatment. PGI-S Scale is a categorical scale and asks the participant to "rate the severity of your muscle weakness symptoms today" as one of the following categories: None, Mild, Moderate, Severe, or Very Severe. None means better health status, and best outcome, Very severe means worse health status and worse outcome.

    Time frame: Baseline, Weeks 12, 24, 36, 48

07

Study locations

32 sites
  • University of California, San Diego
    San Diego, California 92093, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30329, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center College of Physician and Surgeon
    New York, New York 10032, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh School of Medicine Children's Hospital of Pittsburgh of UPMC Department of Genetics
    Pittsburgh, Pennsylvania 15224, United States
  • UT Health,Center for the Treatment of Pediatric Neurodegenerative Disease
    Houston, Texas 77030, United States
  • Royal North Shore Hospital Neurology
    Sydney, New South Wales 2065, Australia
  • Calvary Health Care Bethlehem
    Parkdale, Victoria 3162, Australia
  • Department of Neurology, University Clinics Munich
    Munich, Bavaria 80336, Germany
  • Universitaetsklinikum Carl Gustav Carus Dresden Neurologie
    Dresden, Germany
  • Univ of Tubingen, Hertie Institute for Clinical Brain Research
    Tübingen, Germany
  • Semmelweis Egyetem Genomikai Medicina es Ritka Betegsegek
    Budapest, 1083, Hungary
  • University of Pécs, Department of Neurology Klinikai Kozpont - neurologiai Klinika
    Pécs, 7624, Hungary
  • University of Brescia, NeMO Clinical Center for Neuromuscular Diseases
    Gussago, Brescia 25064, Italy
  • Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore
    Rome, Lazio 00168, Italy
  • IRCCS Institute of Neorological Sciences of Bologna Bellaria Hospital
    Bologna, Italy
  • Azienda Ospedaliero Universitaria Policlinico G. Martino
    Messina, 98125, Italy
  • Istituto Nazionale Neurologico Carlo Besta
    Milan, 20133, Italy
  • Azienda Ospedaliero Universitario Pisana, Dipartimento Ambientale di Neuroscienze
    Pisa, 56126, Italy
  • Radboud University Medical Center
    Nijmegen, 6525, Netherlands
  • University of Auckland - Auckland City Hospital, Neurology Department
    Auckland, 1023, New Zealand
  • Helse Bergen HF
    Bergen, 5021, Norway
  • Hospital de la Sta Creu i Sant Pau
    Barcelona, 8025, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital la Fe de Valencia
    Valencia, 46026, Spain
  • University of Cambridge, Department of Clinical Neurosciences
    Cambridge, CB2 0QQ, United Kingdom
  • Queen Square Centre for Neuromuscular Diseases The National Hospital for Neurology and Neurosurgery
    London, WC1N 3BG, United Kingdom
  • Newcastle upon Tyne Hospitals Freeman Hospital
    Newcastle, NE77DN, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Sep 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Dec 17, 2021
StartActual
Apr 29, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Dec 4, 2024
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05162768
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Apr 29, 2022
Primary completion
Sep 30, 2024
Completion
Dec 4, 2024
Last update
Oct 24, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion